Siemens Healthineers Expands Into Molecular Cancer Diagnostics

Siemens Healthineers is broadening its diagnostic portfolio with the acquisition of NEO New Oncology and its next-generation sequencing (NGS) platform. The German startup specializes in the development of both blood-based and tissue-based genomic tests that allow oncologists to better target cancer therapies with less-invasive diagnostics.
Source: Medical Design Online News - Category: Medical Equipment Source Type: news